W
William Stohl
Researcher at University of Southern California
Publications - 174
Citations - 11513
William Stohl is an academic researcher from University of Southern California. The author has contributed to research in topics: B-cell activating factor & T cell. The author has an hindex of 48, co-authored 160 publications receiving 10325 citations. Previous affiliations of William Stohl include University of California, Los Angeles & Rockefeller University.
Papers
More filters
Journal ArticleDOI
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie,Michelle A. Petri,Omid Zamani,Ricard Cervera,Daniel J. Wallace,D. Tegzova,Jorge Sanchez-Guerrero,Andreas Schwarting,Joan T. Merrill,W. Winn Chatham,William Stohl,Ellen M. Ginzler,Douglas R. Hough,Z. John Zhong,William W. Freimuth,Ronald F van Vollenhoven +15 more
TL;DR: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Journal ArticleDOI
Elevated serum B lymphocyte stimulator levels in patients with systemic immune–based rheumatic diseases
TL;DR: BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases.
Journal ArticleDOI
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace,William Stohl,Richard Furie,Jeffrey R. Lisse,James D. McKay,Joan T. Merrill,Michelle A. Petri,Ellen M. Ginzler,W. Winn Chatham,W. Joseph McCune,Vivian Fernandez,Marc Chevrier,Z. John Zhong,William W. Freimuth +13 more
TL;DR: Belimumab was biologically active and well tolerated and the effect of belimumab on the reduction of SLE disease activity or flares was not significant, however, serologically active SLE patients responded significantly better to belicumab therapy plus SOC than to SOC alone.
Journal ArticleDOI
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
William Stohl,Samy Metyas,Soon Min Tan,Gurtej S. Cheema,Bonifacia Oamar,Dong Xu,Viktor Roschke,Youmei Wu,Kevin P. Baker,David M. Hilbert +9 more
TL;DR: Dysregulation ofBLyS over extended periods of time is common in patients with SLE, and Neutralization of BLyS activity with an appropriate BLYS antagonist may be therapeutically beneficial.
Journal ArticleDOI
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard Furie,Michelle Petri,Daniel J. Wallace,Ellen M. Ginzler,Joan T. Merrill,William Stohl,W. Winn Chatham,Vibeke Strand,Arthur Weinstein,Marc Chevrier,Z. John Zhong,William W. Freimuth +11 more
TL;DR: This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.